We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
- Authors
Giuliani, Jacopo; Fiorica, Francesco; Sacchetto, Alfredo; Franceschini, Gianfranco; Vaccari, Ferdinando; Bonetti, Andrea
- Abstract
The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP). We have calculated the mean drug costs (expressed in euros (€)) for patients treated for BTCP. INFS resulted the less expensive towards OTFC and FBT, with 697 440 €versus (vs.) 809 552 €vs. 779 662 €every 100 patients treated for BTCP, respectively. In conclusion, combining drug costs of different biotechnologies (INFS, OTFC and FBT) with the measure of efficacy represented by the reduction of BTCP avoided (incremental cost-effectiveness ratio, ICER), INFS resulted in better cost-effectiveness.
- Subjects
MEDICAL care cost statistics; CANCER pain; DRUG efficacy; ORAL drug administration; FENTANYL; MEDICAL care costs; INTRANASAL medication; COST effectiveness; BUCCAL administration; BREAKTHROUGH pain; PAIN management; BIOTECHNOLOGY
- Publication
Journal of Oncology Pharmacy Practice, 2021, Vol 27, p445
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/1078155220983429